Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT1070250117
jRCT1070250117Not yet recruitingNot Applicable

Evaluation of the Efficacy, Safety, and Patient Self-Assessment in Reducing Downtime by Use of Membrane Formation Collagen Hydrogel Following Ablative CO2 Fractional Laser Resurfacing

Not provided0 sites5 target enrollmentStarted: TBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
5
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Other
Allocation
Single Arm Study

Eligibility Criteria

Ages
20age old over to 60age old under (—)
Sex
All

Inclusion Criteria

  • •Healthy Asian people aged 20~
  • •Skin type: 3-4
  • •Someone is available in this study's schedule.
  • •Someone who is less revealed in sunlight during the observational period.
  • •Someone who can accept researchers' orders.

Exclusion Criteria

  • •Someone who has received the facial treatment for aesthetic purposes within 90 days before this study.
  • •Chemical Sensitivity, especially alcoholic sensitivity.
  • •Someone subject to the contraindication of Ablative CO2 Fractional Laser Resurfacing.
  • •Someone whom the researcher considers not appropriate for this study.

Investigators

Sponsor
Not provided

Similar Trials

Recruiting
Phase 1
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.
2025-522243-17-00Philogen S.p.A.96
Recruiting
Phase 2
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma
2022-501822-39-00Philogen S.p.A.113
Completed
Phase 2
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00Sanofi-Aventis Recherche & Developpement59
Recruiting
Phase 1
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies
2024-511453-22-00Kumquat Biosciences Inc.112
Recruiting
Phase 1
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.
2025-523587-20-00Gruenenthal GmbH24